Indapta Therapeutics, INC.
2 clinical trials · Sponsor
◉ Watch Indapta Therapeutics, INC.
| Record | Firm | Date |
|---|---|---|
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis (NCT06677710) | Indapta Therapeutics, INC. | 2026-06-30 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers (NCT06119685) | Indapta Therapeutics, INC. | 2023-10-25 |
Track Indapta Therapeutics, INC. automatically
Every clearance here is in the API, with alerts when new ones post.